Anavex Life Sciences Corp (AVXL)

[Jonjones325]

FWIW Our AI friend says:

As of my last update in January 2022, the European Medicines Agency (EMA) recognizes brain atrophy as a relevant biomarker for Alzheimer's disease in the context of clinical trials and drug development. Brain atrophy, particularly in specific regions of the brain, can be indicative of neurodegenerative diseases like Alzheimer's. In clinical trials, changes in brain volume or structure measured through imaging techniques such as MRI can serve as important indicators of disease progression or response to treatment. However, the specific opinions or guidelines regarding brain atrophy as a biomarker for Alzheimer's may evolve over time as new research and evidence emerge. It's essential to consult the latest EMA guidelines or statements for the most up-to-date information.